What peptides does Hims plan to launch by the end of this year, and what are their intended uses according to CEO Andrew Dudum?

According to CEO Andrew Dudum, Hims will sell peptides already legal for manufacturing by the end of the year, including NAD+, sermorelin, and glutathione — used to support metabolic function, weight loss, and immune function, respectively.

Why are Wall Street analysts skeptical that Hims' upcoming peptide offerings will drive meaningful revenue growth in 2024?

Analysts are skeptical because the peptides Hims plans to launch this year — like NAD+ — are already widely available, so they lack the 'release the floodgates' demand associated with peptides still under FDA review; additionally, much peptide purchasing occurs through grey or unauthorized markets, making it difficult to assess the revenue impact of Hims’ legal NAD+ offering.

As Hims prepares for peptides launch, Wall Street cautious on prospects this year

Aug 12, 2026

Hims & Hers Health plans to launch legally available peptides in 2026, but analysts remain cautious about near-term revenue growth due to FDA regulatory uncertainties and limited differentiation from existing grey market offerings.

reuters

2026-08-12

As Hims prepares for peptides launch, Wall Street cautious on prospects this year

As Hims prepares for peptides launch, Wall Street cautious on prospects this year

FAQ